Methodology of phase I study in Japan

Area of Science:

• Oncology
• Clinical Pharmacology
• Drug Development

Background:

• Phase I studies are critical for evaluating new antitumor agents before broader clinical trials.
• Leading Japanese institutions actively participate in these early-stage investigations.
• The development of less toxic, more effective anticancer drugs presents unique challenges.

Purpose of the Study:

• To review and analyze the methodologies employed in phase I studies of antitumor agents in Japan.
• To discuss the evolution of dose-finding strategies and toxicity prediction in preclinical and clinical settings.
• To explore efficient approaches for conducting complex phase I studies.

Main Methods:

• Review of historical and current phase I study methodologies in Japan.
• Analysis of preclinical toxicology data and its correlation with clinical toxicities.
• Examination of dose calculation methods, including comparisons to rodent and animal models.

Main Results:

• Preclinical toxicology accurately predicted gastrointestinal and hematopoietic toxicities but overestimated renal/hepatic and underestimated neurologic/skin toxicities.
• Initial dose calculations have shifted from LD50 comparisons to using rodent LD10 or large animal TLD.
• Metabolite-induced toxicities complicate phase I studies for novel antitumor agents.

Conclusions:

• Phase I study methodologies in Japan have evolved, particularly in dose determination and toxicity assessment.
• Predicting clinical toxicities remains challenging, necessitating careful monitoring and adaptive study designs.
• Further refinement of phase I study approaches is needed to efficiently develop safer, more effective antitumor agents.